CBD Concentration Within Advertised Spec.

CBD Concentration Within Advertised Spec.

The product label, advertising and website list 3.0mg of active Cannabinoids per lozenge tablet on the bottle (see label below). These are essentially an infused breath mint that comes in a retail boxed 60ct bottle; intended for 1 month supply. The lab at Mastix Medica randomly tested samples from the entire manufacturing batch, some 200,000 tablets by volume. Here’s the breakdown on the lab results:

Total Cannabinoids from Sample 1: 2.7mg of Cannabinoids per tablet, within 10% of advertised target with an upper limit of 3.6mg per tablet. These were taken from random samples among tens of thousands of tablets during manufacturing. The manufacturing and lab results confirm that not more than two tablets differ by more than 10% of the average weight of any twenty tablets.

The second Cannabinoid test was conducted by Phytosphere Systems, and was sampled from a four kilogram batch of bulk hemp-oil, specifically used for manufacturing the ArisiTol product. Constituents are: CBD 15.01%, CBC 1.07%, CBG at .92% and CBN .15% by dry weight. The test found .55% THC, which is .03% upon consumption.